US › Healthcare

Kodiak Sciences Inc (KOD)

US · Healthcare · Biotechnology

$42.89+7.68%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-58.2M

Profit YoY

-1.2%

EPS

$-0.94

EPS estimate

$-1.01

EPS came in at -0.94 against a street estimate of -1.01 — a beat of 6.9%.

Key statistics

Market cap

$2.49B

Forward P/E

0.0

P/B

23.22

Book value

$1.81

EPS (TTM)

$-4.17

52-week high

$47.84

52-week low

$7.40

50-day MA

$37.52

200-day MA

$30.36

Beta

2.21

Analyst view

Analysts rate Kodiak Sciences Inc a hold (1 buy, 2 hold, 3 sell out of 6) with an average price target of $62.67.

Shareholding

Insiders

5.18%

Institutions

99.67%

Largest institutional holders

Fund	Stake
Baker Bros Advisors LP	31.83%
BlackRock Inc	6.29%
Vanguard Group Inc	3.70%
State Street Corp	3.60%
T. Rowe Price Associates, Inc.	3.26%
BRAIDWELL LP	2.91%
Vanguard Capital Management, LLC	2.74%
The Goldman Sachs Group Inc	2.70%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kodiak Sciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.